Innoviva Inc (INVA) — closed signal from March 20, 2026
Partial Published before the outcome was known, scored automatically when the window closed on June 18, 2026 — +1.9% at the close.
Predicted vs. what happened
What happened
Reached 77% of the predicted growth at its peak, without hitting the target.
The thesis — published March 20, 2026
Recent company news connects a share buyback plan, a higher price target, and a clearer plan for product revenue growth. Shares trading near their short-term 20-day trend suggest they are not overstretched, which could allow a measured rise if cash generation proves consistent. The thesis relies more on company-specific strength than broad market support.
Primary drivers
- Share buyback lowers downside risk and signals management confidence
- Product and royalty mix gives company-specific paths for growth
- Healthy cash on the balance sheet reduces need for outside funding
- Higher target helped reinforce the narrative of a turnaround
How it played out
INVA: rose 10.8% but missed the target
Lyra published INVA at $22.07 with expected growth of 14% and a $25.16 target. The thesis pointed to the share buyback, the product and royalty mix, available cash, and a higher price target. It expected these company-specific factors to support a measured rise if cash generation remained consistent.
The shares reached a peak of $24.45 on April 20, a gain of 10.8%. That peak stayed below the $25.16 target, so the target was never reached. INVA ended the window at $22.49. The thesis partially played out because the price rose toward the target but gave back most of that gain before the window closed.
What happened during the window
On May 6, Innoviva reported first-quarter revenue of $98.0 million and net product sales of $41.4 million. On June 16, its subsidiary announced an exclusive distribution and licensing agreement with Dr. Reddy's for XACDURO in selected international markets.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.